ROCKAWAY, N.J. , Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the third quarter of 2022. Financial Guidance Preliminary unaudited financial
Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022 ROCKAWAY, N.J. , July 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today
Record revenue will be at least $2.1 million ; approximately 65% growth over second quarter 2021 June 30, 2022 , cash and cash equivalents balance of approximately $26.6 million ROCKAWAY, N.J. , July 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a
Record revenue of approximately $2.8M expected for the three months ended March 31, 2023 ; 46% increase over first quarter of 2022 Revenue in first full quarter of Truvaga sales of approximately $147,000 expected ROCKAWAY, N.J. , April 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc.
BASKING RIDGE, N.J. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on its commercial operations, clinical development programs, and introduced select preliminary unaudited guidance for the fourth
Third q uarter 2021 revenue expected to be approximately $1.5 million Net cash used to fund operations in the third quarter 2021 of approximately $3.5 million ROCKAWAY, NJ , Oct. 12, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today
Second-Quarter 2021 revenue expected to be approximately $ 1.3 million Net cash used to fund operations in the second quarter 2021 of approximately $ 3.2 million Follow on offering subsequent to June 30, 2021 added $18 . 8 million to cash balance ROCKAWAY, NJ , July 13, 2021 (GLOBE NEWSWIRE)
Record r evenue from product sales will be approximately $1.9M ; approximately 60% growth over first quarter 2021 March 31, 2022 , cash balance of approximately $29.9M ROCKAWAY, N.J. , April 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage
First-quarter 2021 revenue expected to be more than $1.1 million Net cash used for the first quarter 2021 of approximately $4.1 million ROCKAWAY, NJ , April 13, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an
BASKING RIDGE, N.J. , April 17, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020.